KRAS and neoplasm: MAPK reactivation, PI3K alterations, additional RET mutations, K-RAS mutations, BRAF mutations and MET or FGFR1 amplifications are among the resistance mechanisms observed in tumor cells during this study, and several of these mechanisms are often observed in the same patient, suggesting that polyclonal resistance may occur regularly [155].